Adults with persistent acne can ask a dermatologist whether twice-daily clascoterone 1% cream fits their treatment plan. Evidence through 2026 supports it as a non-antibiotic option that targets oil production and inflammation in adult male and female skin. Clascoterone, sold as Winlevi, is a first-in-class topical androgen-receptor inhibitor for acne vulgaris.
It received FDA approval on Aug. 26, 2020 for patients aged 12 and older, according to the Drugs.com FDA approval history FDA approval history. It is thought to compete with dihydrotestosterone in oil glands, limiting excess sebum and inflammation without systemic anti-androgen pills.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does clascoterone target adult acne?
- What did the clinical trials show?
- What side effects should adults discuss?
- How can adults ask about access and daily use?
How does clascoterone target adult acne?
The drug blocks androgen signals inside sebocytes, the cells that make sebum. Less androgen signaling means less stimulus for oily buildup and inflamed lesions. The Springer Dermatology and Therapy review describes this local receptor competition as central to its action 2025 clascoterone review.
Adults can use it on face, chest, shoulders, or back. It is prescription-only and applied as a thin layer morning and evening. Dermatologists may pair it with a retinoid or benzoyl peroxide because it does not rely on antibiotics.
What did the clinical trials show?
Two 12-week vehicle-controlled phase 3 trials enrolled 1,440 patients with moderate-to-severe facial acne. Twice-daily clascoterone produced higher treatment success and fewer inflammatory and noninflammatory lesions than vehicle. The JAMA Dermatology report presents these trials as the main efficacy basis pivotal trial summary.
A 9-month open-label extension followed 609 patients from those trials. Improvement continued with persistent twice-daily face and trunk use up to 12 months. The safety profile remained favorable during extended treatment.
What side effects should adults discuss?
Most reactions are local skin irritation. Redness, dryness, itching, and peeling can occur where the cream is applied. Moisturizer timing, cleanser choice, and retinoid spacing often matter for comfort.
The FDA label also warns of rare reversible adrenal-gland signal suppression. After two weeks, laboratory changes appeared in 1 of 20 adults and 2 of 22 adolescents. All cases normalized within four weeks off treatment.
How can adults ask about access and daily use?
The 2024 American Academy of Dermatology guidelines conditionally recommend topical clascoterone with high certainty in the evidence. The same guidelines flag high cost as a barrier to equitable access. Insurance coverage, prior authorization, and pharmacy price therefore deserve direct questions.
Practical use requires steady twice-daily application to affected areas. Adults should ask about duration before judging benefit, signs of irritation to report, and interaction with current products. Bring a list of all skin products so the dermatologist can plan layering and irritation control.
- Current prescription and over-the-counter acne products and moisturizers
- Past response to antibiotics, retinoids, benzoyl peroxide, or hormonal treatment
- Preferred morning and evening routine for face, chest, shoulder, or back use
- Insurance rules, refill cost, and what to do if a dose is missed
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: Questions Adults With Persistent Acne Can Ask a Dermatologist
- Milk, Dairy, and Acne Evidence Revisited in 2026: How Adults With Persistent Acne Can Test Changes Without Overrestricting
- High-Glycemic Diets and Acne Evidence Revisited in 2026: How Adults With Persistent Acne Can Test Changes Without Overrestricting